利培酮
药代动力学
药理学
生物利用度
活性代谢物
代谢物
口服
化学
医学
内科学
精神分裂症(面向对象编程)
精神科
作者
Kyoung Sin Lee,Song Wha Chae,Joon Hee Park,Jung Hyun Park,Jong Min Choi,Sandy Jeong Rhie,Hwajeong Lee
出处
期刊:Xenobiotica
[Taylor & Francis]
日期:2012-12-04
卷期号:43 (3): 303-310
被引量:11
标识
DOI:10.3109/00498254.2012.731092
摘要
1. The interactions between herbal dietary supplements and therapeutic drugs have emerged as an important issue and P-glycoprotein (P-gp) has been reported as one of the significant factors of these interactions. 2. The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone, in rats. 3. To determine the plasma levels of risperidone and 9-hydroxyrisperidone in rats, a HPLC method was developed using a liquid-liquid acid back extraction. When risperidone (6 mg/kg) was co-administered with silymarin (40 mg/kg) to rats orally, the C(max) of 9-hydroxyrisperidone was significantly increased to1.3-fold (p < 0.05), while the other pharmacokinetic parameters did not show any significant differences. Expanding the experiment where rats were repeatedly administered with silymarin for 5 days prior to giving risperidone, the C(max) of risperidone and 9-hydroxyrisperidone were significantly increased to 2.4-fold (p < 0.001) and 1.7-fold (p < 0.001), respectively, and the AUC(0-t), as well to 1.7-fold (p < 0.05) and 2.1-fold (p < 0.01), respectively. 4. The repeated exposures of silymarin, compared to single administration of silymarin, increased oral bioavailability and affected the pharmacokinetics of risperidone and 9-hydroxyrisperidone, by inhibiting P-gp.
科研通智能强力驱动
Strongly Powered by AbleSci AI